Hamlet Pharma regains patent rights for BAMLET
The board of Hamlet Pharma has decided to accept a proposal from Linnane Pharma to terminate the patent license agreement from May 12, 2020.Hamlet Pharma AB and Linnane Pharma AB entered into a licensing agreement on 12 May 2020, for the development of BAMLET; a complex formed by bovine alpha-lactalbumin and oleic acid. According to the agreement, Linnane Pharma would under Hamlet Pharma's patents develop the product BAMLET for non-pharmaceutical use. Since then, Linnane Pharma has worked intensively to drive the project forward. However, the board of Linnane Pharma has acknowledged